New York lawmakers won't pass a 340B drug program protection bill this session, disappointing hospitals and health centers ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...

A federal judge in Maine has put the brakes on a pilot program that would have enabled biopharma companies to offer rebates instead of discounts as part of the 340B program beginning Jan. 1, 2026.

The 340B Drug Pricing Program is under pressure from multiple directions: pharmacy benefit manager litigation, drugmaker contract pharmacy restrictions, and a federal rebate pilot that courts have ...

With post-pandemic Medicaid enrollments on the decline and expected to fall further, revenue cycle leaders warn that ...

Select hospitals have refused to share data to prove they’re not double-dipping drug discounts, Lilly said. Hospitals, which ...

Forbes contributors publish independent expert analyses and insights. I am a cable news contributor and professor of journalism. This voice experience is generated by AI. Learn more. This voice ...

This approach would aim to raise the same amount of revenue that was previously generated by covered entities’ arbitrage of 340B drugs without the perverse incentives perpetuated by the current ...

On November 25, 2025, the Centers for Medicare & Medicaid Services (CMS) published the maximum fair prices (MFPs) for the second group of drugs that were subject to the Inflation Reduction Act (IRA) ...

Although 340B does not operate through the tax code, its economic effects mirror those of a tax expenditure. Recognizing it as such would not prejudge the program’s merits but would force a ...

CVS Faces Lawsuit for Allegedly Pocketing $250 Million in Drug Savings Meant for Uninsured Patients ...

For the second time, the Centers for Medicare & Medicaid Services (CMS) modified the Request for Applications (RFA) document for manufacturers, which sets forth the terms of the “GENErating cost ...